Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212270 | 0.92 | NPC1 (0.39) | NPC1RAB9AKDM4CPDE4BPDE3A | |
| SCHEMBL3219605 | 0.82 | PDE4B (0.39) | NPC1RAB9AKDM4CPDE4BPDE3A | |
| SCHEMBL3203863 | 0.80 | PDE4B (0.44) | NPC1RAB9APDE4BPDE3AEP300 | |
| SCHEMBL3226376 | 0.78 | NPC1 (0.38) | NPC1RAB9AKDM4CPDE4BPDE3A | |
| SCHEMBL13240799 | 0.78 | PDE4B (0.43) | NPC1RAB9APDE4BPDE3AEP300 | |
| SCHEMBL3210906 | 0.77 | PDE4B (0.43) | PDE4BPDE3ACXCR2 | |
| SCHEMBL20521763 | 0.75 | KDM4C (0.38) | NPC1RAB9AKDM4CL3MBTL1EP300 | |
| SCHEMBL2969811 | 0.74 | HTR2C (0.36) | NPC1RAB9AKDM4CHTR2CSLC6A4 | |
| SCHEMBL3207493 | 0.73 | MEN1 (0.37) | NPC1RAB9AHTR2CSLC6A4EP300 | |
| SCHEMBL13425113 | 0.72 | PDE4B (0.70) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058310-A1 | PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | NPC1 4252/4885RAB9A 580/4885KDM4C 1053/4885 |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | PDE5A, PDE3A, PDE2A | NPC1 4569/4885RAB9A 1502/4885KDM4C 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.